98%
921
2 minutes
20
The PAQosome (particle for arrangement of quaternary structure) is a 12-subunit HSP90 co-chaperone involved in the biogenesis of several human protein complexes. Two mechanisms of client selection have previously been identified, namely, the selective recruitment of specific adaptors and the differential use of homologous core subunits. Here, we describe a third client selection mechanism by showing that RPAP3, one of the core PAQosome subunits, is phosphorylated at several Ser residues in HEK293 cells. Affinity purification coupled with mass spectrometry (AP-MS) using the expression of tagged RPAP3 with single phospho-null mutations at Ser116, Ser119, or Ser121 reveals binding of the unphosphorylated form to several proteins involved in ribosome biogenesis. phosphorylation assays indicate that the kinase CK2 phosphorylates these RPAP3 residues. This finding is supported by data showing that pharmacological inhibition of CK2 enhances the binding of RPAP3 to ribosome preassembly factors in AP-MS experiments. Moreover, the silencing of PAQosome subunits interferes with ribosomal assembly factors' interactome. Altogether, these results indicate that RPAP3 phosphate group addition/removal at specific residues modulates binding to subunits of preribosomal complexes and allows speculating that PAQosome posttranslational modification is a mechanism of client selection.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/acs.jproteome.1c00938 | DOI Listing |
Br J Haematol
September 2025
Department of Hematology, The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Refractory cytomegalovirus (CMV) infection is a severe complication following umbilical cord blood transplantation (UCBT). Antiviral agents, the standard first-line therapy, are limited by toxicity and resistance without robust T-cell immunity. We evaluated third-party donor (TPD)-derived CMV-specific T cells (CMVSTs) as a treatment option.
View Article and Find Full Text PDFAnn Surg Oncol
September 2025
Division of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Soft tissue sarcomas (STS) are a heterogeneous group of rare malignant tumors arising from mesenchymal tissues, with extremity and superficial trunk STS (eSTS) comprising the majority of cases. The management of localized eSTS requires a multidisciplinary approach to optimize oncologic and functional outcomes. This review outlines the natural history, diagnostic workup, and treatment principles for localized eSTS, emphasizing the role of histology-specific considerations in guiding management strategies.
View Article and Find Full Text PDFJ Imaging Inform Med
September 2025
Department of Diagnostic, Interventional and Pediatric Radiology (DIPR), Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.
Large language models (LLMs) have been successfully used for data extraction from free-text radiology reports. Most current studies were conducted with LLMs accessed via an application programming interface (API). We evaluated the feasibility of using open-source LLMs, deployed on limited local hardware resources for data extraction from free-text mammography reports, using a common data element (CDE)-based structure.
View Article and Find Full Text PDFEur J Pediatr
September 2025
Paediatric Pain and Palliative Care Service, Department of Women's and Children's Health, University Hospital of Padua, Padua, Italy.
Purpose: This study aimed to describe the structure, patient characteristics, and preliminary clinical outcomes of a dedicated interdisciplinary outpatient clinic for paediatric chronic and complex pain in Italy, with a focus on the feasibility of implementing a biopsychosocial care model.
Methods: We conducted a retrospective review of all patients referred to the Paediatric Specialised Pain Clinic of the University of Padua between January 2023 and May 2024. Data on demographics, clinical diagnoses, pain characteristics, treatments, and follow-up outcomes were collected.
Biochem Genet
September 2025
Department of Medical Biology, Cerrahpasa Faculty of Medicine, Istanbul University Cerrahpasa, Kocamustafapasa, 34098, Istanbul, Turkey.
Glioblastoma is the most aggressive and malignant tumor of the central nervous system. Current treatment options, including surgical excision, radiotherapy, and chemotherapy, have Limited efficacy, with a median survival rate of approximately 15 months. To develop novel therapeutics, it is crucial to understand the underlying molecular mechanisms driving glioblastoma.
View Article and Find Full Text PDF